JMP Securities on Friday night downgraded Generation Bio to Market Perform from Outperform after the company delayed its translational plans to focus on a next-generation DNA construct that better evades innate immunity. While iqDNA represents a “significant improvement” in evading innate immunity, absent a clear timeline to translation of the lead hemophilia A program, a downgrade is warranted, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GBIO:
- Generation Bio downgraded to Market Perform from Outperform at JMP Securities
- Generation Bio participates in a conference call with JPMorgan
- Generation Bio to develop iqDNA, discontinue ceDNA development
- Generation Bio downgraded to Market Perform from Outperform at TD Cowen
- Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
